Progress and Challenges of Messenger RNA Vaccines in the Therapeutics of NSCLC.

ABSTRACT: The introduction of immune checkpoint inhibitors in the therapeutics of non-small cell lung cancer (NSCLC) has been a game-changer in the management of patients with lung cancer; however, challenges do exist since a non-negligible subset of patients does not respond to therapy. Various immunotherapeutic anticancer strategies have been increasingly developed in recent years, including monoclonal antibodies, adoptive T-cell therapy, and vaccines. Fueled by their rapid drug development and successful implementation during the COVID-19 pandemic, messenger RNA (mRNA) vaccines represent an emerging therapeutic approach in other fields of medicine, including oncology. Several clinical trials are currently being conducted to assess the safety and efficacy of mRNA vaccines regarding a variety of so

SUBMITTER: Kiousi E 

PROVIDER: S-EPMC10705317 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature